SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-23-032052
Filing Date
2023-11-14
Accepted
2023-11-14 17:21:14
Documents
71
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20230930_10q.htm   iXBRL 10-Q 1455789
2 EXHIBIT 31.1 ex_596349.htm EX-31.1 8659
3 EXHIBIT 31.2 ex_596350.htm EX-31.2 8645
4 EXHIBIT 32.1 ex_596351.htm EX-32.1 4501
5 EXHIBIT 32.2 ex_596352.htm EX-32.2 4397
  Complete submission text file 0001437749-23-032052.txt   7976141

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA navb-20230930.xsd EX-101.SCH 72935
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20230930_def.xml EX-101.DEF 552956
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20230930_lab.xml EX-101.LAB 449332
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20230930_pre.xml EX-101.PRE 578218
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20230930_cal.xml EX-101.CAL 49846
65 EXTRACTED XBRL INSTANCE DOCUMENT navb20230930_10q_htm.xml XML 1139046
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 231408038
SIC: 2835 In Vitro & In Vivo Diagnostic Substances